Safety of micafungin in infants: insights into optimal dosing

Bibliography

• Benjamin DK Jr, Stoll BJ, Fanaroff AA, Neonatal candidiasis among extremely low birth weight infants: risk factors, mortality rates, and neurodevelopmental outcomes at 18 to 22 months. Pediatrics 2006;117(1):84-92
   PubMed Web of Science ®Google Scholar
• Stoll BJ, Hansen N, Fanaroff AA, Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network. Pediatrics 2002;110(2 Pt 1):285-91
   PubMed Web of Science ®Google Scholar
• Benjamin DK Jr, DeLong ER, Steinbach WJ, Empirical therapy for neonatal candidemia in very low birth weight infants. Pediatrics 2003;112(3 Pt 1):543-7
   PubMed Web of Science ®Google Scholar
• Friedman S, Richardson SE, Jacobs SE, Systemic Candida infection in extremely low birth weight infants: short term morbidity and long term neurodevelopmental outcome. Pediatr Infect Dis J 2000;19(6):499-504
   PubMed Web of Science ®Google Scholar
• Kawaguchi C, Arai I, Yasuhara H, Efficacy of micafungin in treating four premature infants with candidiasis. Pediatr Int 2009;51(2):220-4
   PubMed Web of Science ®Google Scholar
• Odio CM, Araya R, Pinto LE, Caspofungin therapy of neonates with invasive candidiasis. Pediatr Infect Dis J 2004;23(12):1093-7
   PubMed Web of Science ®Google Scholar
• Smith PB, Steinbach WJ, Cotten CM, Caspofungin for the treatment of azole resistant candidemia in a premature infant. J Perinatol 2007;27(2):127-9
   PubMed Web of Science ®Google Scholar
• Wagner C, Graninger W, Presterl E, The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications. Pharmacology 2006;78(4):161-77
   PubMed Web of Science ®Google Scholar
• Warnock DW. Trends in the epidemiology of invasive fungal infections. Nippon Ishinkin Gakkai Zasshi 2007;48(1):1-12
   PubMedGoogle Scholar
• Mora-Duarte J, Betts R, Rotstein C, Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002;347(25):2020-9
   PubMed Web of Science ®Google Scholar
• Reboli AC, Rotstein C, Pappas PG, Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007;356(24):2472-82
   PubMed Web of Science ®Google Scholar
• Tawara S, Ikeda F, Maki K, In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi. Antimicrob Agents Chemother 2000;44(1):57-62
   PubMed Web of Science ®Google Scholar
• Ikeda F, Wakai Y, Matsumoto S, Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis. Antimicrob Agents Chemother 2000;44(3):614-18
   PubMed Web of Science ®Google Scholar
• Messer SA, Diekema DJ, Boyken L, Activities of micafungin against 315 invasive clinical isolates of fluconazole-resistant Candida spp. J Clin Microbiol 2006;44(2):324-6
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Boyken L, Hollis RJ, In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol 2008;46(1):150-6
   PubMed Web of Science ®Google Scholar
• CLSI. Method for antifungal disk diffusion susceptibility testing of yeasts; approved standard. Document M27-A3. In: Wayne PA, editor, 3rd edition. Clincal and Laboratory Standards Institute; 2008
   Google Scholar
• Sakaeda T, Iwaki K, Kakumoto M, Effect of micafungin on cytochrome P450 3A4 and multidrug resistance protein 1 activities, and its comparison with azole antifungal drugs. J Pharm Pharmacol 2005;57(6):759-64
   PubMed Web of Science ®Google Scholar
• van Burik JA, Ratanatharathorn V, Stepan DE, Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004;39(10):1407-16
   PubMed Web of Science ®Google Scholar
• Hiemenz J, Cagnoni P, Simpson D, Pharmacokinetic and maximum tolerated dose study of micafungin in combination with fluconazole versus fluconazole alone for prophylaxis of fungal infections in adult patients undergoing a bone marrow or peripheral stem cell transplant. Antimicrob Agents Chemother 2005;49(4):1331-6
   PubMed Web of Science ®Google Scholar
• de Wet N, Llanos-Cuentas A, Suleiman J, A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis 2004;39(6):842-9
   PubMed Web of Science ®Google Scholar
• Sirohi B, Powles RL, Chopra R, A study to determine the safety profile and maximum tolerated dose of micafungin (FK463) in patients undergoing haematopoietic stem cell transplantation. Bone Marrow Transplant 2006;38(1):47-51
   PubMed Web of Science ®Google Scholar
• Mycamine (package insert). Deerfield, IL: Astellas Pharma; 2005
   Google Scholar
• Seibel NL, Schwartz C, Arrieta A, Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother 2005;49(8):3317-24
   PubMed Web of Science ®Google Scholar
• Kusuki S, Hashii Y, Yoshida H, Antifungal prophylaxis with micafungin in patients treated for childhood cancer. Pediatr Blood Cancer 2009;53(4):605-9
   PubMed Web of Science ®Google Scholar
• Freire AA, Stevenson P, Undre N. Pharmacokinetics of micafungin in pediatric patients with invasive candidiasis and candidemia [abstract A-772]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 17 – 20 September 2007; Chicago, IL; 2007
   Google Scholar
• Heresi GP, Gerstmann DR, Reed MD, The pharmacokinetics and safety of micafungin, a novel echinocandin, in premature infants. Pediatr Infect Dis J 2006;25(12):1110-15
   PubMed Web of Science ®Google Scholar
• Hope WW, Mickiene D, Petraitis V, The pharmacokinetics and pharmacodynamics of micafungin in experimental hematogenous Candida meningoencephalitis: implications for echinocandin therapy in neonates. J Infect Dis 2008;197(1):163-71
   PubMed Web of Science ®Google Scholar
• Smith PB, Walsh TJ, Hope W, Pharmacokinetics of an elevated dosage of micafungin in premature neonates. Pediatr Infect Dis J 2009;28(5):412-15
   PubMed Web of Science ®Google Scholar
• Kawada M, Fukuoka N, Kondo M, Pharmacokinetics of prophylactic micafungin in very-low-birth-weight infants. Pediatr Infect Dis J 2009;28(9):840-2
   PubMed Web of Science ®Google Scholar
• Benjamin DK Jr, Smith PB, Arrieta A, Safety and pharmacokinetics of repeat-dose micafungin in young infants. Clin Pharmacol Ther 2010;87(1):93-9
   PubMed Web of Science ®Google Scholar
• Benjamin DK Jr, Poole C, Steinbach WJ, Neonatal candidemia and end-organ damage: a critical appraisal of the literature using meta-analytic techniques. Pediatrics 2003;112(3 Pt 1):634-40
   PubMed Web of Science ®Google Scholar
• Cohen-Wolkowiez M, Smith PB, Mangum B, Neonatal Candida meningitis: significance of cerebrospinal fluid parameters and blood cultures. J Perinatol 2007;27(2):97-100
   PubMed Web of Science ®Google Scholar
• Fernandez M, Moylett EH, Noyola DE, Candidal meningitis in neonates: a 10-year review. Clin Infect Dis 2000;31(2):458-63
   PubMed Web of Science ®Google Scholar
• Mycamine [US Prescribing Information]. Astellas Pharma: Deerfield I, 2008
   Google Scholar
• Hope WW, Smith PB, Arrieta A, Population pharmacokinetics of micafungin in neonates and young infants. Antimicrob Agents Chemother 2010;54(6):2633-7
   PubMed Web of Science ®Google Scholar
• Lopez Sastre JB, Coto Cotallo GD, Fernandez Colomer B. Neonatal invasive candidiasis: a prospective multicenter study of 118 cases. Am J Perinatol 2003;20(3):153-63
   PubMed Web of Science ®Google Scholar
• Linder N, Klinger G, Shalit I, Treatment of candidaemia in premature infants: comparison of three amphotericin B preparations. J Antimicrob Chemother 2003;52(4):663-7
   PubMed Web of Science ®Google Scholar
• Scarcella A, Pasquariello MB, Giugliano B, Liposomal amphotericin B treatment for neonatal fungal infections. Pediatr Infect Dis J 1998;17(2):146-8
   PubMed Web of Science ®Google Scholar
• Natarajan G, Lulic-Botica M, Aranda JV. Refractory neonatal candidemia and high-dose micafungin pharmacotherapy. J Perinatol 2009;29(11):738-43
   PubMed Web of Science ®Google Scholar